3 terminated, 2 completed. 5 Phase 3, 1 Phase 2.
By phase and status
Follow bempegaldesleukin: new trials by email Literature Review of bempegaldesleukin trials Research Report on bempegaldesleukin
Trials (filtered) newest first · largest first
All 5 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) Bempegaldesleukin, Pembrolizumab - Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer Phase 2 / Phase 3 Terminated 1 2022-03-09 2023-01-12 Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence Bempegaldesleukin, Nivolumab - Melanoma, Melanoma Stage III Phase 3 Terminated 765 2020-07-27 2023-04-21 A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Nivolumab, Radical cystectomy (RC), Bempegaldesleukin - Bladder Cancer, Bladder Tumor Phase 3 Completed 114 2020-02-05 2024-06-27 A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) bempegaldesleukin, sunitinib, nivolumab - Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma Phase 3 Terminated 623 2018-12-18 2023-04-11 A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma NKTR-214, Nivolumab - Melanoma Phase 3 Completed 783 2018-09-21 2025-04-01
Conditions studied Melanoma (2) · Carcinoma, Renal Cell (1) · Head and Neck Neoplasms (1) · Kidney Neoplasms (1) · Skin Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Urinary Bladder Neoplasms (1)
Sponsors Nektar Therapeutics (3) · Bristol-Myers Squibb (2)
Countries United States (5) · Australia (4) · Austria (4) · Greece (4) · Italy (4) · Russia (4) · Argentina (3) · Brazil (3) · Czechia (3) · France (3) · Germany (3) · Israel (3) · Mexico (3) · Netherlands (3) · New Zealand (3)
Results publications PMID 32723187 , PMID 35073733 , PMID 37651676 , PMID 38838287
NIH funding 2018 (2)